Barclays Raises GE HealthCare (GEHC) PT to $87 Following Q4 Beat, Strong 2026 Outlook

Core Viewpoint - GE HealthCare Technologies Inc. (NASDAQ:GEHC) is currently considered one of the best IPO stocks to buy, with multiple analysts raising their price targets following strong Q4 2025 results and an optimistic outlook for 2026 [1][2][3]. Analyst Ratings and Price Targets - Barclays increased its price target for GE HealthCare to $87 from $86, maintaining an Equal Weight rating, citing a solid Q4 2025 performance and a 2026 outlook that exceeds market expectations [1]. - Stifel analyst Rick Wise raised the price target to $98 from $95 with a Buy rating, expressing encouragement regarding the company's prudent outlook for 2026 following the earnings call [2]. - Morgan Stanley also raised its price target for GE HealthCare to $85 from $80, maintaining an Equal Weight rating, and updated its risk-reward assessment based on Q4 2025 results that surpassed expectations [3]. Company Overview - GE HealthCare Technologies Inc. develops, manufactures, and markets products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the US, Canada, and internationally [4].